Presentation / Poster

At the Formulation & Delivery US 2024 conference, Crystal Formulation Services (Crystal Pharmatech's CDMO BU) will present a technical case study centered on the formulation and development process of First-In-Human (FIH) enteric-coated tablets at three dose strengths for an amorphous prodrug highly susceptible to hydrolysis under both acidic and basic conditions. We will delve into the scientific approaches employed to mitigate degradation pathways, ensure product stability through carefully selected excipients and optimized manufacturing techniques, and how material science-based approaches can lead to successful FIH product development within tight timelines.